Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-27
2005-12-27
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S010100, C514S019300, C514S249000, C514S253090, C514S422000
Reexamination Certificate
active
06979697
ABSTRACT:
A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.
REFERENCES:
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 6040145 (2000-03-01), Huber et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 6100234 (2000-08-01), Huber et al.
patent: 6258597 (2001-07-01), Bachovchin et al.
patent: 6300314 (2001-10-01), Wallner et al.
patent: 6355614 (2002-03-01), Wallner
patent: 6503882 (2003-01-01), Huber et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6692753 (2004-02-01), Huber et al.
patent: 6703238 (2004-03-01), Bachovchin et al.
patent: 6770628 (2004-08-01), Wallner et al.
patent: 2003/0158114 (2003-08-01), Wallner et al.
patent: 2003/0199563 (2003-10-01), Robl et al.
patent: 2003/0212044 (2003-11-01), Huber et al.
patent: 2004/0077601 (2004-04-01), Adams et al.
patent: 2004/0152192 (2004-08-01), Bachovchin et al.
patent: 158109 (1982-12-01), None
patent: 294176 (1991-09-01), None
patent: 294711 (1991-10-01), None
patent: 296075 (1991-11-01), None
patent: 19834591 (2000-02-01), None
patent: 995440 (2000-04-01), None
patent: 1084705 (2001-03-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 93/10127 (1993-05-01), None
patent: WO 94/03055 (1994-02-01), None
patent: WO 94/03055 (1994-02-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 97/11689 (1997-04-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/00439 (1998-01-01), None
patent: WO 98/25644 (1998-06-01), None
patent: WO 98/25644 (1998-06-01), None
patent: WO 98/50046 (1998-11-01), None
patent: WO 98/50046 (1998-11-01), None
patent: WO 98/50066 (1998-11-01), None
patent: WO 99/28474 (1999-06-01), None
patent: WO 99/28474 (1999-06-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/56296 (2000-09-01), None
patent: WO 01/14318 (2001-03-01), None
Bristol et al. Inhibition of CD26 . . . Blood. Jun. 15, 1995. vol. 85, No. 12, pp. 3602-3609.
Shioda et al. Anti-HIV-1 and chemotactic activites. . . PNAS USA. 1998, vol. 95, No. 11, pp. 6331-6336.
Oravecz et al. Regulation of the receptor specificity. . . J. Exp. Med. 1997, vol. 186, No. 11, pp. 1865-1872.
Kelly et al. Immunosuppressive Boronic Acid Dipeptides. . . J. Am. Chem. Soc. 1993, vol. 115, pp. 12637-12638.
Snow et al. Studies on Proline Boronic Acid Dipeptide Inhibitors. . . J. Am. Chem. Soc. 1994, vol. 116, pp. 10860-10869.
U.S. Appl. No. 60/135,861, filed May 25, 1999.
Amara et al., HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. Jul. 7, 1997;186(1):139-46.
Arenzana-Seisdedos et al., HIV blocked by chomokine antagonist. Nature. Oct. 3, 1996; 383(6599):400.
Atchison et al., Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines, Science. Dec. 13, 1996;274(5294):1924-6.
Bachovchin et al., Inhibition of IgAl proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J Biol Chem. Mar. 5, 1990;265(7):3738-43.
Benkirane et al., The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4. J Virol. Nov. 1995;69(11):6904-10.
Berson et al., A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol. Sep. 1996;70(9):6288-95.
Bleul et al., The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry, Nature. Aug. 29, 1996;382(6594):829-33.
Bleul et al., A highly efficacious lymphocte chemattractant, stromal cell-derived factor 1 (SDF-1) J Exp Med. Sep. 1, 1996;184(3):1101-9.
Bristol et al., Inhibition of CD26 enzyme activity with pro-boropro stimulates rat granulocyte/macrophage colony formation and thymocyte proliferation in vitro. Blood. Jun. 15, 1995;85(12):3602-9.
Brubaker et al., Circulating and tissue forms of the intestinal growth factor growth factor, glucagon-like peptide-2. Endocrinology. Nov. 1997;138(11):4837-43.
Brubaker et al., Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol. Jun. 1997;272(6 Pt 1):E1050-8.
Coutts et al., Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem. May 10, 1996;39(10):2087-94.
Deacon et al., Dipepidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig, Diabetes. May 1998;47(5):764-9.
Drucker et al., Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. Jul. 1997;15(7):673-7.
Drucker, Glucagon-like peptides. Diabetes. Feb. 1998;47(2):159-69. Review.
Feil et al., Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem Biophys Res Commun. Jun. 9, 1998;247(1):38-45.
Flentke et al., Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A. Feb. 15, 1991;88(4):1556-9.
Hesselgesser et al., Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol. Jan. 15, 1998;160(2):877-83.
Heveker et al., Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides. Curr Biol. Mar. 26, 1998;8(7):369-76.
Heymann et al., [Has dipeptidyl peptidase IV an effect on blood pressure and coagulation?] Klin Wochenschr. Jan. 2, 1984;62(1):2-10. Review. German.
Hoffmann et al, Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. Dec. 20, 1993:336(1):61-4.
Kelly et al., Immunosuppresive boronic acid dipeptides: corrlation between conformation and activity. J Am Chem Soc. 1993; 115(26): 12637-12638.
Kieffer et al., Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. Aug. 1995;136(8):3585-96.
Kim et al., CK beta-11/macrophage inflammatory protein-3 beta/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells. J Immunol. Mar. 1, 1998;160(5):2418-24.
Oberlin et al., The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. Aug. 29, 1996;382(6594):833-5. Erratum in: Nature Nov. 21, 1996;384(6606):288.
Oravecz et al., Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidly peptidase IV (CD26)-mediated cleavage. J Exp Med. Dec. 1, 1997;186(11):865-72.
Reinhold et al., CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology. Jan. 1996;195(1):119-28.
Schall et al., Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct pop
Point Therapeutics, Inc.
Russel Jeffrey Edwin
Wolf Greenfield & Sacks P.C.
LandOfFree
Regulation of substrate activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of substrate activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of substrate activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486393